Back to Search
AFSHIN DOWLATI, MD
MD
Hematology & Oncology Physician
NPI: 1528084852IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
35-076391(OH)
Education
OTHER
Class of 1992
Research & Publications (20)
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.
PMID 19399502·Cancer Chemother Pharmacol·2009
3-trial
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.
PMID 18316562·Clin Cancer Res·2008
3-trial
SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.
PMID 18043125·Anticancer Drugs·2008
8-other
Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.
PMID 17328989·Lung Cancer·2007
3-trial
Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer.
PMID 16034518·Invest New Drugs·2005
3-trial
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.
PMID 16278419·Clin Cancer Res·2005
3-trial
Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy.
PMID 15078989·Mol Cancer Ther·2004
8-other
Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
PMID 14676117·Clin Cancer Res·2003
3-trial
Combination chemotherapy with topotecan for non-small cell lung cancer.
PMID 14565511·Lung Cancer·2003
8-other
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
PMID 12067983·Cancer Res·2002
3-trial
Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days.
PMID 11304785·J Clin Oncol·2001
3-trial
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
PMID 11269740·Cancer Chemother Pharmacol·2001
3-trial
Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
PMID 11325486·Lung Cancer·2001
3-trial
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
PMID 11595684·Clin Cancer Res·2001
7-preclinical
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.
PMID 19011760·Invest New Drugs·2009
3-trial
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
PMID 18414865·Cancer Chemother Pharmacol·2009
3-trial
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
PMID 18670776·Cancer Chemother Pharmacol·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 11100 EUCLID AVE
CLEVELAND, OH 44106 - Phone
- (216) 844-8500
Quick Facts
- NPI
- 1528084852
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile